Evidence map›Paper›PMID 32892678›Full record

ArticlePharmaceutical development and technology2020

A surfactant-stripped cabazitaxel micelle formulation optimized with accelerated storage stability.

Boyang Sun, Huang Jing, Moustafa T Mabrouk, Yumiao Zhang, Honglin Jin, Jonathan F Lovell

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical development and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Topical Drug Delivery of Concentrated Cabazitaxel in an α-Tocopherol and DMSO Solution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Boyang SunDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.
Huang JingCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Moustafa T MabroukDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.
Yumiao ZhangSchool of Chemical Engineering and Technology, Tianjin University, Tianjin, China.
Honglin JinCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jonathan F LovellDepartment of Biomedical Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.
University at Buffalo, State University of New York · USHuazhong University of Science and Technology · CNTianjin University · CNUnion Hospital · CN

Funding

Targeting Tumors with Resealable Nanovesicles Permeabilized by NIR LightDP5OD017898 · OD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LOVELL, JONATHAN F · 2013 to 2017
$1.9M
NIH HHS DP5 OD017898
6 · The paper itself

Abstract

Pluronic (Poloxomer) micelles can solubilize cabazitaxel (CTX), a second-generation taxane, and then be subjected to low-temperature "surfactant-stripping" to selectively remove loose and free surfactant, thereby increasing the drug-to-surfactant ratio. We previously found that the addition of certain other co-loaded hydrophobic cargo to the micelles can result in stabilized, surfactant-stripped cabazitaxel (sss-CTX) micelles, which resist drug aggregation in aqueous storage, a common challenge for taxanes. Here, we show that elevated temperatures can accelerate the aggregation of sss-CTX micelles, thereby enabling rapid optimization of formulations with respect to the type and ratio of co-loader used for stabilization. A sss-CTX micelle formulation was developed using mifepristone as the co-loader, at a 60% mass ratio to the CTX. Drug release, hemolysis and complement activation were investigated

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, Lewis LungDrug StabilityDrug StorageExcipientsHumansHydrophobic and Hydrophilic InteractionsLung NeoplasmsMaleMiceMice, Inbred C57BLMicellesPoloxamerPolysorbatesSurface-Active AgentsAntineoplastic AgentscabazitaxelExcipientsMicellesPoloxamerPolysorbatesSurface-Active AgentsTaxoidscabazitaxelDrug deliverymicellessurfactantstaxanes

Identifiers

PMID32892678
PMCPMC7695035
OpenAlexW3083818772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.